The question
Rapamycin and Human Healthspan
This is the specific idea being tested.
The Hypothesis Critic · A guide for everyone
Rapamycin and Human Healthspan
Rapamycin and Human Healthspan
What you need to knowRapamycin has strong animal longevity evidence, but intermittent dosing has not yet established improved physical function in otherwise healthy older adults.Relative explanatory fit: Alternative ranked ahead
Why the alternative fits better: Late-life heterogeneous mice 19587680 and C57 BL/6 function/survival 23682161 are positive; nfκb 1 healthspan without lifespan 30468013 maps an outcome boundary. Direct human functional trial 41985884 lacks benefit; sex, genetic, exercise, metabolic and formulation differences constrain transfer.
Review summary
Claim assessed: Intermittent low-dose oral rapamycin improves physical function in otherwise healthy adults aged 50 and older.
Finding: Preregistered primary-subclaim aggregation returns SC2 Γ. Strong preclinical biology and selected exploratory human signals coexist with a directly relevant negative-direction functional primary null. Markers, body composition and other-indication clinical results do not identify sustained physical-function benefit for the registered regimen and population. This scores the stated positive proposition without a preset verdict or safety recommendation.
Key points
- SC1: Intermittent rapamycin engages mTOR-related biology in older adults. — HSEF Γ, Moderate confidence.
- SC2: Intermittent rapamycin improves physical function against placebo. — HSEF Γ, Moderate confidence.
- SC3: Immune markers or animal lifespan establish slower human aging. — HSEF Γ, Moderate confidence.
- SC4: Senolytic combinations reproduce established rapamycin healthspan benefit in humans. — HSEF Α, Moderate confidence.
Verdict and review details
- Evidence grade
- HSEF Γ — Mechanistically plausible, partial system support
- Confidence
- Moderate
- Framework
- HSEF v5.3
- Review date
- Literature cutoff
- Published
- Review attribution (recorded)
- Codex
Evidence scope: 55 primary reports; literature cutoff 2026-10-13; source examination UTC date 2026-10-13; bounded critical review, not exhaustive systematic review.
The grade applies to the stated claim. Model rankings and individual subclaim grades remain separate from the overall causal-evidence grade.
Full scientific assessment and references · Scorecard (JSON) · Review source (Markdown)
The result at a glance
Rapamycin has strong animal longevity evidence, but intermittent dosing has not yet established improved physical function in otherwise healthy older adults.
Best fit in this review
Animal regimen and context determine real benefit
Late-life heterogeneous mice 19587680 and C57 BL/6 function/survival 23682161 are positive; nfκb 1 healthspan without lifespan 30468013 maps an outcome boundary. Direct human functional trial 41985884 lacks benefit; sex, genetic, exercise, metabolic and formulation differences constrain transfer.
Evidence for the stated claim
Plausible, not established
A higher rank means a better fit to the evidence in this comparison. It does not prove every part of the leading explanation.
Which explanation fits?
Another explanation fits better.
A separate question from the causal evidence grade
How does this explanation compare with alternatives?
Alternative ranked aheadThe reviewed hypothesis ranks 3 among 4 models compared; 1 alternative model(s) hold first rank for this stated claim.
Claim under review: rank 3 among 4 compared models.
Leading explanation: Animal regimen and context determine real benefit.
Position in this comparison: Between leading and last ranks.
The causal grade asks how well the stated causal claim is established. This comparison asks which of the assessed explanations fits the reviewed findings better. A leading explanation can remain unproven. Models can overlap or include the tested mechanism; an alternative ahead does not make that mechanism irrelevant. These ordinal ranks apply within this review; they do not measure the size of a difference or rank scientific strength across topics.
Idea being tested · rank 3
Rapamycin and Human Healthspan
Plausible, not established for the stated claim.
Best fit in this review · rank 1
Animal regimen and context determine real benefit
Late-life heterogeneous mice 19587680 and C57 BL/6 function/survival 23682161 are positive; nfκb 1 healthspan without lifespan 30468013 maps an outcome boundary. Direct human functional trial 41985884 lacks benefit; sex, genetic, exercise, metabolic and formulation differences constrain transfer.
These explanations can overlap. Ranking their fit to the evidence is separate from deciding how firmly a cause has been established.
See all the explanations compared
Rank 1: Animal regimen and context determine real benefit — Rapamycin causes lifespan and selected health/function benefits in defined model contexts; translation to intermittent human function remains separate.
Rank 2: Target and immune effects differ from generalized healthspan — Defined mTOR interventions can change immune phenotypes or specific infection risk without establishing healthy-human physical benefit.
Rank 3: Intermittent mTOR modulation improves older-human function — Weekly low-dose oral rapamycin causes sustained physical-function improvement in otherwise healthy older adults.
Rank 4: Senolytics have separate clinical scope — Senescent-cell targeting may benefit defined conditions through another mechanism, without reproducing an established rapamycin benefit.
What this means
?
Plausible, not established
Rapamycin has strong animal longevity evidence, but intermittent dosing has not yet established improved physical function in otherwise healthy older adults.
Evidence rating: Γ · Moderate confidence. How the evidence was assessed.
The important distinction
Late-life heterogeneous mice 19587680 and C57 BL/6 function/survival 23682161 are positive; nfκb 1 healthspan without lifespan 30468013 maps an outcome boundary. Direct human functional trial 41985884 lacks benefit; sex, genetic, exercise, metabolic and formulation differences constrain transfer.
A result about how a disease works is a separate question from whether a treatment improves health.
From an idea to an explanation
Seeing two things together does not prove one causes the other.
What is observed?
Look for the proposed factor and the outcome, in the people or systems covered by the claim.
What else explains it?
Animal regimen and context determine real benefit. Late-life heterogeneous mice 19587680 and C57 BL/6 function/survival 23682161 are positive; nfκb 1 healthspan without lifespan 30468013 maps an outcome boundary. Direct human functional trial 41985884 lacks benefit; sex, genetic, exercise, metabolic and formulation differences constrain transfer.
What test tells them apart?
A registered multicenter 52–104 week placebo-controlled trial of verified commercial-equivalent intermittent doses in otherwise healthy adults aged 50 or older, with balanced exercise strata, objective function as primary and prospective dose/exposure/sex analyses, followed by independent replication.
What to test next
What evidence would make the answer clearer?
A useful next question
A registered multicenter 52–104 week placebo-controlled trial of verified commercial-equivalent intermittent doses in otherwise healthy adults aged 50 or older, with balanced exercise strata, objective function as primary and prospective dose/exposure/sex analyses, followed by independent replication.
Change the proposed cause
Check that the intended change really happened.
Measure the relevant outcome
Allow for other factors and compare with suitable controls.
Check whether it holds up
Look for independent confirmation and the limits of the effect.
These are questions for research, not a claim that the proposed studies have already succeeded.
Read the scientific study designs
Proposed tests: 1 test design(s) are registered in the scorecard.
In plain terms, researchers would change the proposed cause, check that it changed as intended, then measure a meaningful outcome while controlling plausible alternatives. The result should be able to support or count against the claim—not only show that a pathway exists.
Experiment 1: Registered boundary experiment
Study design: A registered multicenter 52–104 week placebo-controlled trial of verified commercial-equivalent intermittent doses in otherwise healthy adults aged 50 or older, with balanced exercise strata, objective function as primary and prospective dose/exposure/sex analyses, followed by independent replication.
What would be measured: Prespecified chair-standing, walking capacity, strength and validated functional response; falls/disability secondary; lean mass, immune/p21 and clock markers separate intermediate outcomes
Important controls: Verified formulation and exposure, target engagement, prespecified baseline health/activity and sex/dose strata, balanced exercise/contact, blinded assessors, ITT missing-data handling and complete infection/metabolic/wound adverse-event capture
Result that would support the claim: Clinically meaningful function improves versus placebo across a prespecified context with supported target specificity and an acceptable benefit-harm profile
Result that would count against it: Precise unchanged or worse function despite appropriate exposure and target effect, or composition change without primary functional benefit; adverse-event shifts constrain the regimen
Explore the evidence
Read the complete scientific review.
Follow the studies, detailed comparisons and evidence ratings behind this guide.
Open the scientific review →